Novo Nordisk (NVO) Announces Wegovy Approved in the US for Cardiovascular Risk Reduction in People with Overweight or Obesity and Established Cardiovascular Disease
Go back to Novo Nordisk (NVO) Announces Wegovy Approved in the US for Cardiovascular Risk Reduction in People with Overweight or Obesity and Established Cardiovascular Disease| NOVO-NORDISK A/S (NYSE: NVO) | Delayed: 45.88 +2.69 (6.23%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $43.19 | 52 Week High | $59.00 | |||
| Open | $44.01 | 52 Week Low | $32.80 | |||
| Day High | $46.45 | P/E | N/A | |||
| Day Low | $43.90 | EPS | $0.00 | |||
| Volume | 17,136,782 | |||||
